2-Fluoro-3-methylbenzoic acid | CAS:315-31-1

We serve 2-Fluoro-3-methylbenzoic acid CAS:315-31-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2-Fluoro-3-methylbenzoic acid

Chemical Name:2-Fluoro-3-methylbenzoic acid
CAS.NO:315-31-1
Synonyms:2-Fluor-3-methyl-benzoesaeure; 
2-Fluoro-3-methylbenzoicacid; 
3-methyl-2-fluorobenzoic acid;
Molecular Formula:C8H7FO2
Molecular Weight:154.13800
 
Physical and Chemical Properties:
Density:1.225;
Melting point:114-116oC;
Boiling point:197.031oC;
Flash point:72.962oC;
Index of Refraction:1.472;
 
Specification:
Appearance:White powder
Purity(GC):≥99.0%
Moisture:≤0.5%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate for organic synthesis



Contact us for information like 2-Fluoro-3-methylbenzoic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-methyl-2-fluorobenzoic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Fluor-3-methyl-benzoesaeure Use and application,2-Fluoro-3-methylbenzoicacid technical grade,usp/ep/jp grade.


Related News: In 2016, the export volume of China’s specialty drug substances reached US $ 3.53 billion, accounting for 13.8% of the total drug substances.Elaidic Acid manufacturer On Friday, the Trump administration announced it will deny entry to foreign nationals who have traveled in China in the last 14 days, starting Sunday.2-(7-Methoxynaphthalen-1-yl)ethanamine supplier The iLet Bionic Pancreas System is a pocket-sized, wearable investigational medical device that is designed to autonomously control blood-sugar levels.2-chloro-4-methyl-3-nitropyridine vendor The safety and effectiveness of TCM is still debated in China, where it has both adherents and skeptics.As proof-of-principle for the unique advantages arising from selecting a single engineered iPSC clone for the production of CAR T-cell therapy, the scientists assessed 747 clones after engineering a pool of cells using CRISPR. It was found that only about 2% of clones met the Company’s standards for overall quality including containing both bi-allelic disruption of the TCR, proper insertion of the CAR into the TRAC locus without random transgene integrations, and no evidence of off-target genomic modifications or translocations.